pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Novo Nordisk Inc · news · pharmadog
← back to Novo Nordisk Inc
News mentioning Novo Nordisk Inc
167
stories
15d
The top 12 companies hiring in biopharma now
biospace
15d
Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday
fiercebiotech
16d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
16d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
16d
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
16d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
16d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
16d
A COPD drug from China draws $115M in venture funding
biopharma dive
16d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
Novo Nordisk eyes bolt-on deals as pipeline disappointments pile up
endpoints
16d
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
fiercebiotech
16d
Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data
fiercebiotech
16d
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
biospace
17d
Novo vs. Lilly: Q2's cardiometabolic grudge match
endpoints
17d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
17d
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
18d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
18d
Amgen hit with cybersecurity breach, patient data affected
biospace
18d
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
21d
Novo setback casts doubt on a new way to treat heart disease
biopharma dive
21d
Novo Nordisk rocked by late-stage cardiovascular drug failure
endpoints
21d
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
21d
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
stat
21d
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
21d
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
fiercebiotech
22d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
23d
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
23d
7 companies hiring in New York now
biospace
23d
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
biospace
← prev
page 2 of 6
next →
